期刊文献+

双色荧光原位杂交技术检测乳腺癌石蜡切片人类表皮生长因子受体2基因扩增 被引量:1

Apply dual-color fluorescent in situ hybridization for detection of Her-2 gene in breast carcinoma paraffin section
暂未订购
导出
摘要 目的:应用荧光原位杂交技术检测乳腺癌组织人表皮生长因子受体2(human epidermal growth factor receptor 2,Her-2)基因扩增情况。并对操作方法进行优化。方法:收集2008年4月至2008年10月期间我院乳甲科进行手术治疗的乳腺癌患者的癌组织病理切片,采用荧光原位杂交(FISH)技术检测Her-2基因扩增情况,并与免疫组化结果相比较,分析两者的相关性,同时优化操作方法。结果:收集的40例乳腺癌石蜡切片中,免疫组化检测Her-2蛋白表达(+++)有6例,(++)有22例,(+)有7例,(-)有5例。其中Her-2蛋白表达(+++)的标本FISH检测结果均为阳性,基因扩增与蛋白表达的符合率为100%;Her-2蛋白表达(++)的标本FISH结果有6例阳性,16例阴性,基因扩增与蛋白表达的符合率为27.3%。Her-2蛋白表达(+)及(-)的标本FISH结果均为阴性。Her-2蛋白表达(++)及以上的标本基因扩增与蛋白表达的符合率达到42.9%(r=0.584,P<0.01)。结论:FISH检测乳腺癌Her-2基因扩增的结果与IHC检测的蛋白表达结果符合率较好,可作为乳腺癌Her-2基因检测的一项新技术;在具体操作时,应注意严格控制切片厚度、消化时间及变性杂交温度等因素。 Objective To apply dual-color fluorescence in situ hybridization for detection of the expressions of Her- 2 gene in breast carcinoma tissues, and to find some modifications of the FISH method. Methods To collect the pathological section of breast cancer tissues from 40 patients with primary infiltrating ductal carcinomas who were received surgery in our hospital from April 2008 to October 2008. Her-2 gene amplification were detected by FISH and compared with the results of IHC. The correlation between these results was analyzed and optimization to FISH was discussed. Results In the 40 tissue specimens of breast carcinoma, IHC detected 6 specimens with Her-2 score (+++), 22 specimens with score (++), 7 specimens with score (+) and 5 specimens score negative. FISH identified gene amplification in 100% (6/6) specimens with an IHC score (+++), and in 27.3% (6/22)specimens with an IHC score (++), thus the concordant ratio between IHC and FISH was 42.9%(12/28). The two results showed significant relation(r = 0.584,P 〈 0.01 ) o The negative result were in all specimens with an IHC score (+) and (-). Conclusion The results of Her-2 gene amplification detected by FISH have well concordance with the protein expression results detected by IHC .As a new method for detection of Her-2 gene, the thickness of the sections , the post-hybridization washing temperature and time should be strictly controlled.
出处 《实用医学杂志》 CAS 北大核心 2009年第21期3685-3687,共3页 The Journal of Practical Medicine
关键词 乳腺肿瘤 HER-2基因 FISH 免疫组织化学 相关性 Breast neoplasms Her-2 gene Fluorescence in Situ Hybridization IHC Correlation
  • 相关文献

参考文献8

  • 1Gilboat L, Ben-Lerys R, Yarden Y, et al . Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of new receptors with coated pits [J]. J Biol Chem, 1995, 270(13) :7061.
  • 2郑绘霞,阚秀.乳腺癌HER-2/neu基因检测与Herceptin治疗[J].实用癌症杂志,2001,16(2):222-224. 被引量:3
  • 3Dennis J S, Gary M C, Stenven G W, et al. Human breast cancer : correlation of relapse and survival with amplification of the Her-2/ neu oncogene [J]. Science, 1987, 235(4785) : 177-182.
  • 4江泽飞,王涛,姚开泰.针对HER-2的乳腺癌分子靶向药物赫赛汀治疗新动向[J].中国实用内科杂志,2005,25(8):681-683. 被引量:9
  • 5Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting Her-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility [J]. Mod Pathol, 2005,18 (8) : 1015- 1021.
  • 6Dietel M, Ellis I O, H tier H, et al. Comparison of automated silver enhanced in situ hybridizations (SISH) and fluorescence ISH ( FISH) for the validation of Her-2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists [J]. Virchows Arch, 2007, 4(51) : 19-25.
  • 7Cuadros M, Villegas R. Systematic review of Her2 breast cancer testing [J]. Appli Immunohistochem Mole Morphol, 2009,17 ( 1 ) : 1-7.
  • 8Rasmussen B B, Andersson M, Christensen I J, et al. Evaluation of and quality assurance in Her2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between Her-2 status and other prognostic variables [J]. Acta Oncol, 2008,47(4) :784-788.

二级参考文献6

  • 1Lai R, Dang CT, Malkin MG, et al. The risk of central nervous system metastases after Trastuzumab therapy in patients with breast carcinoma. Cancer, 2004, 101:810-816.
  • 2Bell R, Verma S, Untch M, et al. Maxizing clinical benefit with trastuzumab. Semin Oncol, 2004, 31:35-44.
  • 3Slamon DJ, Leyland - Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001,344: 783- 792.
  • 4Bangemann N, Kuhle A, Ebert A, et al. Capecitabine combined with trastu.zurnab in the therapy of intensive pretreated HER2 -overexpressing metastatic breast cancer. Proc Eur Soc Clin Oncol,2000, 11:143 (abstr653P).
  • 5Hones A, Leyland- Jones B. Optimizing treatment of HER2 -positive metastatic breast cancer. Semin Onool, 2004, 31 (Supp110): 29-34.
  • 6Heodoulou M, Carnpos S, Batist G, et al. TLC 1399 and Herceptin (H) is safe in advanced breast cancer (ABC) : final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol, 2002, 21 :55a (abstr 216).

共引文献10

同被引文献12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部